echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Amgen/BeiGene's new anti-cancer drug approved in China

    Amgen/BeiGene's new anti-cancer drug approved in China

    • Last Update: 2021-08-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    According to the latest announcement on the website of China's State Food and Drug Administration, the carfilzomib for injection (carfilzomib, trade name: Kyprolis) jointly developed by Amgen and BeiGene has been officially approved in China


    Screenshot source: reference [1]

    Proteasomes (proteasomes) in cells can break down damaged or no longer needed proteins, which play an important role in the normal function and growth of cells


    In 2016, carfilzomib was approved by the US FDA as a monotherapy or a combination therapy with dexamethasone or dexamethasone + lenalidomide to treat patients with relapsed or refractory MM


    In a phase 3 clinical trial called ASPIRE, 792 patients with relapsed or refractory MM received carfilzomib combined with lenalidomide and dexamethasone (KRd) combination regimen or lenalidomide and dexamethasone (Rd) regimen


    The test results showed that the average OS of the patients receiving KRd therapy was 48.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.